Who Paid My Doc
Seth Pollack
Hematology & Oncology Chicago, IL Medical Doctor
NPI 1528234143 CMS profile 748732
676 N Saint Clair St Ste 850, Chicago, IL 60611
General payments
$154,773
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$3,480,035
Through program year 2025, Seth Pollack of Chicago, IL is reported in the CMS Open Payments database as having received $154,773 across 138 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $3,480,035 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 95th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $43,736 | 39 | |
| 2024 | General | $52,993 | 47 | |
| 2023 | General | $13,113 | 13 | |
| 2022 | General | $16,818 | 17 | |
| 2021 | General | $16,523 | 11 | |
| 2019 | General | $11,590 | 11 |
Beside peers
- Seth Pollack
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to Seth Pollack were reported at $43,736. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | Seth Pollack | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $11,590 | $529 | $121–$2,516 | $163 |
| 2020 | $0 | $339 | $82–$2,213 | $114 |
| 2021 | $16,523 | $263 | $49–$1,965 | $132 |
| 2022 | $16,818 | $416 | $103–$2,395 | $149 |
| 2023 | $13,113 | $542 | $125–$2,646 | $160 |
| 2024 | $52,993 | $692 | $141–$3,008 | $164 |
| 2025 | $43,736 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 116 billing codesPaid by Medicare
$1,352,303
Medicare patients
225
Services billed
49,378
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 72% | |
| Ischemic heart disease | 39% | |
| Cancer | 39% | |
| Arthritis | 38% | |
| Chronic kidney disease | 34% | |
| Diabetes | 29% | |
| Heart failure | 27% | |
| Depression | 22% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, nivolumab, 1 mg J9299 | Office | 11 | 6,080 | $149,085 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj J9144 | Office | 14 | 3,420 | $133,823 |
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg J1569 | Office | 33 | 2,670 | $92,619 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg Q5119 | Office | 16 | 1,540 | $24,831 |
| Injection, methylprednisolone sodium succinate, 5 mg J2919 | Office | 31 | 4,150 | $946 |
| Injection, methylprednisolone sodium succinate, up to 125 mg J2930 | Office | 12 | 75 | $346 |
| Injection, fosaprepitant, 1 mg J1453 | Office | 18 | 3,000 | $342 |
| Injection, palonosetron hcl, 25 mcg J2469 | Office | 28 | 320 | $216 |
| Injection, granisetron hydrochloride, 100 mcg J1626 | Office | 16 | 230 | $58 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 32 | 436 | $39 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
5 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| OGSIVEO |
|
$19,989 | — | — |
| QINLOCK |
|
$7,745 | — | — |
| TAZVERIK |
|
$6,533 | — | — |
| Turalio |
|
$3,273 | — | — |
| Fyarro |
|
$51 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
138 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology & Oncology in Illinois
Mohamad Khair Khasawneh
Hematology & Oncology · Maywood, IL
Michael Bishop
Hematology & Oncology · Chicago, IL
Jamile Shammo
Hematology & Oncology · Chicago, IL
John Berry
Hematology & Oncology · Berwyn, IL
Young Kwang Chae
Hematology & Oncology · Chicago, IL
Irfan Mirza
Hematology & Oncology · Chicago, IL
Related records
Hematology & Oncology in Illinois
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Illinois
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.